EARNINGS & CATALYSTS · November 3, 2026
McKesson earnings preview for November 4: specialty growth meets a deal-funding test
McKesson’s November 4 report will test specialty growth and its raised profit outlook. A CVS agreement in principle and a proposed Option Care investment put customer retention, cash generation and deal funding in focus.
| Company | Report date | Window | EPS estimate | Revenue estimate |
|---|---|---|---|---|
| McKesson Corporation (MCK) | November 4, 2026Issuer confirmed | After close | 10.72 | 109.9B |
1) When are earnings, and what is expected?
McKesson has confirmed its second-quarter fiscal 2027 results for November 4, 2026 after close. The quarter ended September 30. Its fiscal year ends in March, so this is a fiscal 2027 report despite occurring in calendar 2026. MarketBeat estimates reviewed on November 3 called for adjusted profit per share of $10.72 and revenue of about $109.90 billion. These are analyst expectations, not reported results. The company’s annual adjusted EPS outlook is $44.20–$45.00, raised in August and reaffirmed with the October 1 CVS announcement.
2) Is growth improving profit quality?
For the June quarter, adjusted EPS rose 20% to $9.93 while GAAP diluted EPS fell to $5.15. GAAP follows standard accounting rules; the adjusted measure removes selected items. A $293 million adjustment to the redemption value of minority interests in Medical-Surgical Solutions reduced GAAP earnings per share. Oncology and multispecialty revenue grew 33%, with adjusted operating profit up 41%. Medical-Surgical adjusted operating profit fell 20%, partly because of product mix and one-time administrative costs. Compare the next segment profits with revenue growth: distributing more high-priced medicines does not automatically produce the same growth in earnings.
3) What do the charts show before the report?
McKesson closed November 2 at $998.38, above its 20-day average of $978.11 and 50-day average of $924.98. Recent trading suggests approximate reference areas of $954–$978 below the price and $1,013–$1,030 above it. A close above $1,030 would clear the recent high area; a close below $954 would weaken the recent low area. The comparison image shows that the shares fell about 2.5% between the May 7 and May 8 closes, and about 0.7% between the August 5 and August 6 closes. Both windows followed after-close reports. These changes include all news affecting the shares during each window; prior earnings beats do not guarantee a positive reaction.
4) How the business makes money
McKesson buys and distributes medicines and medical supplies to pharmacies, health systems and other care providers. It also supports oncology and other specialist practices and provides prescription-access technology. Distribution produces large revenue on relatively thin margins, so product mix, service fees and operating efficiency matter alongside sales. The financial image uses the reported fiscal 2026 segment structure and a March year end.
5) What to watch
The October 1 agreement in principle would extend McKesson’s CVS pharmaceutical distribution relationship through June 2032. That offers longer-term customer visibility, while the next earnings outlook will show how management views demand and profitability. The October 6 definitive agreement for Option Care Health would give CD&R approximately 51% ownership and McKesson approximately 49%. McKesson expects to invest about $1.4 billion. Closing is expected in the first half of calendar 2027, subject to shareholder and regulatory approvals and other conditions. This is a proposed investment, not a completed acquisition. Watch funding, timing and how management balances investment with shareholder returns.
6) Recently reported peers
UnitedHealth reported its third quarter on October 13. Optum Rx revenue was $39.9 billion and operating profit was $1.7 billion, compared with $1.5 billion a year earlier. Adjusted prescriptions fell to 393 million from 414 million. The company linked profit improvement to biosimilar adoption and operating changes; biosimilars are medicines designed to be highly similar to approved biological drugs. UnitedHealth’s group adjusted EPS was $4.69, above the dated $4.14 consensus used in the image. Its shares slipped about 0.2% between the October 12 and October 13 closes. Optum Rx provides useful pharmacy-market context, but its benefit-management model and UnitedHealth’s insurance exposure make group margins and valuation different from McKesson’s. Direct distribution peers Cencora and Cardinal Health are due to report November 4 and November 5, respectively; their upcoming results are another comparison to watch.
7) Risks into the report
Large customers can negotiate pricing or change purchasing arrangements. Drug reimbursement, regulation, product mix and competition can squeeze margins, while acquisitions bring financing, integration and approval risks. Cash flow can vary with inventory and payment timing. Portfolio changes and minority-interest accounting can move GAAP EPS independently of adjusted operating progress, so use consistent profit definitions.